Announcements Trials

Browse Landscape

Phase

Phase 1 25 Phase 2 10 Phase 1/2 7 Phase 3 3 Phase NA 1 Phase 2/3 1

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 22 Fluorouracil 21 Radiotherapy 18 Gemcitabine 17 Docetaxel 16 Oxaliplatin 15 Paclitaxel 14 Carboplatin 13 Capecitabine 13 Bevacizumab 13 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Drug Therapy 10 Cytarabine 9 Saline Solution 7 Magnetic Resonance Spectroscopy 7 Letrozole 7 Dexamethasone 7 Rituximab 6 Nivolumab 6 Methotrexate 6 Exercise 6 Etoposide 6 Electroporation 6 Doxorubicin 6 pembrolizumab 5 Pemetrexed 5 Metformin 5 Melphalan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × selinexor × Clear all

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡